Innate Pharma SA: Innate Pharma Reports First Half 2022 Financial Results and Business Update

Monalizumab and IPH5201 developed in collaboration with AstraZeneca advanced into Phase 3 and 2 clinical trials in lung cancer, triggering $55M in milestone payments Second preclinical asset

Related Keywords

United States ,Russia ,France ,Ukraine ,French ,Ukrainian ,American ,Patrick Langlois ,Enregistrement Universel ,Mondher Mahjoubi ,Bristol Myers Squibb ,Sally Bennett ,Henry Wheeler ,Institut Paoli Calmettes ,Novo Nordisk ,Supervisory Board Of The Company On ,Company Orega Biotech ,Treatment Of Cancer Cutaneous Lymphoma Tumours Group ,Audit Committee ,Nasdaq ,Company Annual Report On Form ,Company On ,Astrazeneca ,European Union ,Board Of The Company On ,Data Monitoring Committee ,European Organisation For Research ,Exchange Commission ,French Financial Markets Authority ,American Association For Cancer Research ,Lymphoma Study Association ,European Society For Medical Oncology ,Euronext ,Euronext Paris ,Chief Executive Officer ,Innate Pharma ,European Organisation ,Cancer Cutaneous Lymphoma Tumours Group ,Company Sponsored Phase ,European Society ,Medical Oncology ,Engager Therapeutics ,Astrazeneca Sponsored Phase ,Clinical Oncologyon April ,Clinical Oncology ,American Association ,Cancer Research ,Annual Meeting ,Independent Data Monitoring Committee ,Programs Option ,American Depositary Shares ,Supervisory Board Meeting ,Supervisory Board ,Orega Biotech ,Natural Killer ,Private Securities Litigation Reform Act ,Risk Factors ,Universal Registration Document ,Annual Report ,Condensed Consolidated Statements ,Financial Position ,Cash Flow ,Sarbanes Oxley Act ,Lumoxiti Agreement ,Transition Agreement ,Settlement Amount ,State Guaranteed Loans ,Statutory Auditors ,Executive Board ,Des March ,Yinnate ,Dharma ,Reports ,First ,Calf ,022 ,Financial ,Results ,Business ,Update ,